Nurix Therapeutics Inc (NRIX)
14.69
+0.15
(+1.03%)
USD |
NASDAQ |
Mar 28, 16:00
14.41
-0.28
(-1.91%)
After-Hours: 20:00
Nurix Therapeutics Cash from Operations (TTM): -81.36M for Nov. 30, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
November 30, 2023 | -81.36M |
August 31, 2023 | -146.01M |
May 31, 2023 | -151.18M |
February 28, 2023 | -165.63M |
November 30, 2022 | -159.81M |
August 31, 2022 | -152.76M |
May 31, 2022 | -136.43M |
Date | Value |
---|---|
February 28, 2022 | -135.05M |
November 30, 2021 | -84.36M |
August 31, 2021 | -73.94M |
May 31, 2021 | -50.10M |
February 28, 2021 | -33.00M |
November 30, 2020 | -0.08M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-165.63M
Minimum
Feb 2023
-0.08M
Maximum
Nov 2020
-105.36M
Average
-135.05M
Median
Feb 2022
Cash from Operations (TTM) Benchmarks
Biogen Inc | 1.547B |
UroGen Pharma Ltd | -76.38M |
Deciphera Pharmaceuticals Inc | -146.70M |
Apellis Pharmaceuticals Inc | -594.74M |
CEL-SCI Corp | -23.07M |